These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 7046693)

  • 41. Probucol further lowers the serum cholesterol of colestipol-treated patients with hypercholesterolemia.
    Schonfeld G; Witztum J; Basich P
    Artery; 1982; 10(2):99-104. PubMed ID: 7092583
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combined effect of probucol and insulin on renal damage in diabetic rats fed a high cholesterol diet.
    Yoshida M; Kimura H; Kyuki K; Ito M
    Eur J Pharmacol; 2006 Oct; 548(1-3):174-80. PubMed ID: 16979162
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans.
    Zhang D; He K; Raghavan N; Wang L; Mitroka J; Maxwell BD; Knabb RM; Frost C; Schuster A; Hao F; Gu Z; Humphreys WG; Grossman SJ
    Drug Metab Dispos; 2009 Aug; 37(8):1738-48. PubMed ID: 19420130
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Experience with probucol in the treatment of hypercholesterolemia.
    Davignon J; Lussier-Cacan S; Dubreuil-Quidoz S; LeLorier J
    Artery; 1982; 10(1):48-55. PubMed ID: 7092576
    [No Abstract]   [Full Text] [Related]  

  • 45. One year experience with probucol, a new hypocholesterolaemic agent.
    Ng AS; Johan A; Quek SS; Tan IK
    Singapore Med J; 1982 Aug; 23(4):191-3. PubMed ID: 7178901
    [No Abstract]   [Full Text] [Related]  

  • 46. New aspects in probucol cardioprotection against doxorubicin-induced cardiotoxicity.
    El-Demerdash E; Ali AA; Sayed-Ahmed MM; Osman AM
    Cancer Chemother Pharmacol; 2003 Nov; 52(5):411-6. PubMed ID: 12879278
    [TBL] [Abstract][Full Text] [Related]  

  • 47. N,N'-diacetyl-L-cystine (DiNAC), the disulphide dimer of N-acetylcysteine, inhibits atherosclerosis in WHHL rabbits: evidence for immunomodulatory agents as a new approach to prevent atherosclerosis.
    Wågberg M; Jansson AH; Westerlund C; Ostlund-Lindqvist AM; Särnstrand B; Bergstrand H; Pettersson K
    J Pharmacol Exp Ther; 2001 Oct; 299(1):76-82. PubMed ID: 11561065
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Clinical assessment of probucol and its therapeutical effect on hypercholesterolaemia (author's transl)].
    Herdová J; Zapletalová J
    Cas Lek Cesk; 1981 Jul; 120(27):832-5. PubMed ID: 7261004
    [No Abstract]   [Full Text] [Related]  

  • 49. Probucol and the QT interval.
    McCaughan D
    Lancet; 1982 Jul; 2(8290):161. PubMed ID: 6123876
    [No Abstract]   [Full Text] [Related]  

  • 50. [Effects of medium-term probucol treatment on plasma lipids and lipoproteins. 16 cases of type IIa and IIb hyperlipoproteinaemia (author's transl)].
    Rouffy J; Chanu B; Bakir R; Goy-Loepper J; Saya C
    Nouv Presse Med; 1980 Oct; 9(40):3014-7. PubMed ID: 7443443
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The metabolism of gemfibrozil.
    Okerholm RA; Keeley FJ; Peterson FE; Glazko AJ
    Proc R Soc Med; 1976; 69 Suppl 2(Suppl 2):11-4. PubMed ID: 828261
    [No Abstract]   [Full Text] [Related]  

  • 52. [Probucol : comparison of its effect with that of a placebo in hyperlipoproteinemia type II].
    Beaumont V
    Nouv Presse Med; 1980 Oct; 9(40):3011-3. PubMed ID: 7443442
    [No Abstract]   [Full Text] [Related]  

  • 53. Influence of native and modified lipoproteins on migration of mouse peritoneal macrophages and the effect of the antioxidants vitamin E and Probucol.
    Trach CC; Wülfroth PM; Severs NJ; Robenek H
    Eur J Cell Biol; 1996 Oct; 71(2):199-205. PubMed ID: 8905298
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Probucol with cholestyramine.
    Bateson MC
    Lancet; 1981 Jul; 2(8237):93. PubMed ID: 6113467
    [No Abstract]   [Full Text] [Related]  

  • 55. Cholestyramine and probucol synergism.
    Nestel PJ
    Ann Intern Med; 1982 Oct; 97(4):622. PubMed ID: 7125430
    [No Abstract]   [Full Text] [Related]  

  • 56. [Establishment of standardized clinical-chemistry normal ranges on toxicology, as demonstrated on the example of serum cholesterol in rhesus monkeys and beagle dogs].
    Metz A; Gürtler J; Deyssenroth H
    Z Versuchstierkd; 1975; 17(3):163-73. PubMed ID: 817534
    [No Abstract]   [Full Text] [Related]  

  • 57. Lack of effect of probucol on serum lipoprotein(a) levels.
    Maeda S; Okuno M; Abe A; Noma A
    Atherosclerosis; 1989 Oct; 79(2-3):267-9. PubMed ID: 2597236
    [No Abstract]   [Full Text] [Related]  

  • 58. Inhibition of the erythrocyte calcium-sensitive potassium channel by probucol.
    Howland JL; Daughtey JN; Donatelli M; Theofrastous JP
    Pharmacol Res Commun; 1984 Nov; 16(11):1057-64. PubMed ID: 6097921
    [No Abstract]   [Full Text] [Related]  

  • 59. [The toxicology of paratertiary butylphenol].
    Babanov GP
    Gig Tr Prof Zabol; 1969 Jul; 13(7):31-3. PubMed ID: 5372662
    [No Abstract]   [Full Text] [Related]  

  • 60. [Contribution to the mechanism of the protective effect of repeated phenolization in mice].
    RASKOVA H; VENECEK J; ZEMAN J; RASKA K; ROTTA J
    Cesk Fysiol; 1960 May; 9():298. PubMed ID: 13739671
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.